BioLife Sciences Inc. Logo

BioLife Sciences Inc.

BLFE

(0.8)
Stock Price

0,00 USD

0% ROA

0% ROE

0x PER

Market Cap.

156.683,00 USD

0% DER

0% Yield

0% NPM

BioLife Sciences Inc. Stock Analysis

BioLife Sciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioLife Sciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-1319.93%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-99.88%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The stock is burdened with a heavy load of debt (4464%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

BioLife Sciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioLife Sciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

BioLife Sciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioLife Sciences Inc. Revenue
Year Revenue Growth
2004 0
2005 5.893 100%
2006 6.457.070 99.91%
2007 8.603.150 24.95%
2008 7.193.392 -19.6%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 411.695 100%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioLife Sciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioLife Sciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioLife Sciences Inc. EBITDA
Year EBITDA Growth
2004 -23.140
2005 -574.151 95.97%
2006 72.974 886.79%
2007 1.705.949 95.72%
2008 1.788.000 4.59%
2015 -21.160 8549.91%
2016 -12.500 -69.28%
2017 -329.130 96.2%
2018 -42.280 -678.45%
2019 171.860 124.6%
2020 -1.243.700 113.82%
2021 0 0%
2022 0 0%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioLife Sciences Inc. Gross Profit
Year Gross Profit Growth
2004 0
2005 5.893 100%
2006 1.129.074 99.48%
2007 1.566.058 27.9%
2008 1.424.672 -9.92%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 -984.540 100%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioLife Sciences Inc. Net Profit
Year Net Profit Growth
2004 -17.860
2005 -479.477 96.28%
2006 -291.193 -64.66%
2007 -2.046.050 85.77%
2008 -3.368.452 39.26%
2015 -28.880 -11563.61%
2016 -19.175 -50.61%
2017 -340.387 94.37%
2018 -52.715 -545.71%
2019 -1.134 -4548.59%
2020 -1.267.738 99.91%
2021 0 0%
2022 0 0%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioLife Sciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 -12
2005 -309 96.1%
2006 -165 -86.67%
2007 -879 81.23%
2008 -669 -31.39%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioLife Sciences Inc. Free Cashflow
Year Free Cashflow Growth
2004 -27.860
2005 -53.018 47.45%
2006 -62.413 15.05%
2007 -285.420 78.13%
2008 -107.591 -165.28%
2016 -11.500 -835.57%
2017 -18.631 38.27%
2018 -12.517 -48.85%
2019 17 73729.41%
2020 -885.269 100%
2021 0 0%
2022 0 0%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioLife Sciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2004 -27.860
2005 -53.018 47.45%
2006 -37.662 -40.77%
2007 -285.420 86.8%
2008 -107.591 -165.28%
2016 -11.500 -835.57%
2017 -18.631 38.27%
2018 -12.517 -48.85%
2019 17 73729.41%
2020 -884.308 100%
2021 0 0%
2022 0 0%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioLife Sciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2004 0
2005 0 0%
2006 24.751 100%
2007 0 0%
2008 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 961 100%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioLife Sciences Inc. Equity
Year Equity Growth
2004 69.951
2005 27.826 -151.39%
2006 250.437 88.89%
2007 59.586 -320.3%
2008 -418.582 114.24%
2015 -126.988 -229.62%
2016 -146.164 13.12%
2017 -183.101 20.17%
2018 -220.866 17.1%
2019 -1.154 -19039.17%
2020 -689.583 99.83%
2021 0 0%
2022 0 0%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioLife Sciences Inc. Assets
Year Assets Growth
2004 86.451
2005 1.652.033 94.77%
2006 3.473.878 52.44%
2007 3.761.803 7.65%
2008 3.041.309 -23.69%
2015 0 0%
2016 0 0%
2017 12.337 100%
2018 1.320 -834.62%
2019 17 -7664.71%
2020 72.718 99.98%
2021 0 0%
2022 0 0%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioLife Sciences Inc. Liabilities
Year Liabilities Growth
2004 16.500
2005 1.624.207 98.98%
2006 3.223.441 49.61%
2007 3.702.217 12.93%
2008 3.459.891 -7%
2015 126.988 -2624.58%
2016 146.164 13.12%
2017 195.438 25.21%
2018 222.186 12.04%
2019 1.171 -18874.04%
2020 762.301 99.85%
2021 0 0%
2022 0 0%
2023 0 0%

BioLife Sciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioLife Sciences Inc. Dividends
Year Dividends Growth

BioLife Sciences Inc. Profile

About BioLife Sciences Inc.

Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. It offers disinfecting wipes, UV sterilization technology, electrostatic disinfection services, anti-microbial textiles, and touchless vending/marketplaces products. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada.

CEO
Mr. Justin De Four
Employee
3
Address
5285 Bradco Blvd
Mississauga, L4W 2A6

BioLife Sciences Inc. Executives & BODs

BioLife Sciences Inc. Executives & BODs
# Name Age
1 Mr. Justin De Four
Founder, Chief Executive Officer & Chairman
70
2 Ms. Nika Jaksic
Chief Operating Officer & Director
70

BioLife Sciences Inc. Competitors